Tools for Preparedness: Triage, screening and patient management for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in acute care settings

Fourth Revision: July 2015
Public Health Ontario

Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, frontline health workers and researchers to the best scientific intelligence and knowledge from around the world.

Public Health Ontario provides expert scientific and technical support to government, local public health units and health care providers relating to the following:

- Communicable and infectious diseases
- Infection prevention and control
- Environmental and occupational health
- Emergency preparedness
- Health promotion, chronic disease and injury prevention
- Public health laboratory services

Public Health Ontario’s work also includes surveillance, epidemiology, research, professional development and knowledge services. For more information, visit www.publichealthontario.ca

How to cite this document:


Public Health Ontario acknowledges the financial support of the Ontario Government.

©Queen’s Printer for Ontario, 2015
Disclaimer

Disclaimer for Best Practice Documents:

This document was developed by the Provincial Infectious Diseases Advisory Committee on Infection Prevention and Control (PIDAC-IPC). PIDAC-IPC is a multidisciplinary scientific advisory body that provides evidence-based advice to Public Health Ontario (PHO) regarding multiple aspects of infectious disease identification, prevention and control. PIDAC-IPC’s work is guided by the best available evidence and updated as required. Best practice documents and tools produced by PIDAC-IPC reflect consensus on what the committee deems prudent practice and are made available as a resource to public health and health care providers. PHO assumes no responsibility for the results of the use of this document by anyone.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to Public Health Ontario. No changes and/or modifications can be made to this document without explicit written permission from Public Health Ontario.

NOTES: This document is intended to provide best practices only. Health care settings are encouraged to work towards these best practices in an effort to improve quality of care.

Provincial Infectious Diseases Advisory Committee (PIDAC)

Tel: 647-260-7100   Email: pidac@oahpp.ca
Tools for Preparedness: Triage, screening and patient management for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in acute care settings, 4th revision.

Published: June 2013

This document is current to July, 2015. New material in this revision is highlighted in mauve in the text (or grey for black-and-white printers).

Summary of Major Revisions:

<table>
<thead>
<tr>
<th>Revision Number</th>
<th>Date of Implementation</th>
<th>Description of Major Changes</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Jul-15</td>
<td>Countries affected by MERS-CoV, morbidity and mortality, and mode of transmission</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>Jul-15</td>
<td>Countries affected by MERS-CoV</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>Jul-15</td>
<td>Travel history and specimens for testing at PHOL</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>Jun-14</td>
<td>Countries affected by MERS-CoV and morbidity and mortality</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>Jun-14</td>
<td>Reporting of occupational illness</td>
<td>7, 9</td>
</tr>
<tr>
<td>2</td>
<td>May-14</td>
<td>Countries affected by MERS-CoV and morbidity and mortality</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>May-14</td>
<td>Symptoms to screen for</td>
<td>9</td>
</tr>
<tr>
<td>1</td>
<td>Oct-13</td>
<td>Visitor limitation</td>
<td>6</td>
</tr>
<tr>
<td>1</td>
<td>Oct-13</td>
<td>Who requires follow-up</td>
<td>7</td>
</tr>
</tbody>
</table>
Authors/Contributors

**PIDAC-IPC MEMBERS:**

**Dr. Matthew Muller, chair**  
Medical Director, IPC  
St. Michael’s Hospital, Toronto

**Chingiz Amirov**  
Director, IPAC  
Baycrest Health Sciences

**Dr. Irene Armstrong**  
Associate Medical Officer of Health  
Toronto Public Health, Toronto

**Anne Bialachowski**  
Manager, IPAC  
St. Joseph’s Health Centre, Hamilton

**Sandra Callery**  
Director, IPAC  
Sunnybrook Health Sciences Centre, Toronto

**Dr. William Ciccotelli**  
Infectious Disease and Medical Microbiology  
Grand River Hospital, Kitchener

**Judy Dennis**  
Manager, IPAC  
Children’s Hospital of Eastern Ontario, Ottawa

**Dr. Susy Hota**  
IPAC Medical Specialist  
University Health Network, Toronto General Hospital, Toronto

**Dr. Allison McGeer**  
Director, Infection Control  
Mount Sinai Hospital, Toronto

**Vydia Nankoosingh**  
Manager, IPAC  
The Scarborough Hospital, Toronto

**Catherine Richard**  
Manager, Occupational Health & Safety Program  
Champlain Community Care Access Centre

**EX-OFFICIO MEMBERS:**

**Erika Bontovics**  
Manager, Infectious Diseases Policy and Programs  
Ministry of Health and Long-Term Care, Toronto

**Dr. Gary Garber**  
Chief, IPAC, Public Health Ontario, Ottawa

**Dr. Leon Genesove**  
Chief Physician, Health Care Unit  
Occupational Health and Safety Branch  
Ministry of Labour, Toronto

**PUBLIC HEALTH ONTARIO STAFF:**

**Dr. Maureen Cividino**  
IPAC Physician

**Tim Cronberry**  
Manager, Regional Infection Control Network

**Cathy Egan**  
Director, IPAC

**Dr. Jennie Johnstone**  
IPAC Physician

**Dr. Kevin Katz**  
IPAC Physician
Acknowledgements

PIDAC-IPC would like to acknowledge the contribution and expertise of the following individuals who participated in developing the first published edition of this document:

**PIDAC-IPC MEMBERS:**
- **Dr. Mary Vearncombe,** chair
  - Medical Director
  - IPAC, Microbiology
  - Sunnybrook Health Sciences Centre, Toronto
- **Dr. Irene Armstrong**
  - Associate Medical Officer of Health
  - Toronto Public Health, Toronto
- **Wendy Beauparlant**
  - LTC Consultant
  - Extendicare (Canada) Inc., Sudbury
- **Anne Bialachowski**
  - Manager, IPAC
  - St. Joseph’s Healthcare, Hamilton
- **Rena Burkholder**
  - IPAC Professional
  - Guelph General Hospital, Guelph
- **Sandra Callery**
  - Director, IPAC
  - Sunnybrook Health Sciences Centre, Toronto
- **Judy Dennis**
  - Manager, IPAC
  - Children’s Hospital of Eastern Ontario, Ottawa
- **Dr. Susy Hota**
  - IPAC Medical Specialist
  - Toronto General Hospital, Toronto
- **Dr. Kevin Katz**
  - Infectious Diseases Specialist and Medical Microbiologist
  - Medical Director, Infection Prevention and Control
  - North York General Hospital, Toronto
- **Dr. Allison McGeer**
  - Director, Infection Control
  - Mount Sinai Hospital, Toronto
- **Shirley McLaren**
  - Director of Client Services
  - CBI Home Health, Kingston
- **Dr. Matthew Muller**
  - Medical Director, IPC
  - St. Michael’s Hospital, Toronto

**EX-OFFICIO MEMBERS:**
- **Erika Bontovics**
  - Manager, Infectious Diseases Policy and Programs
  - Ministry of Health and Long-Term Care, Toronto
- **Dr. Gary Garber**
  - Scientific Lead
  - Medical Director, IPAC
  - Public Health Ontario, Toronto
- **Dr. Leon Genesove**
  - Chief Physician, Health Care Unit
  - Occupational Health and Safety Branch
  - Ministry of Labour, Toronto

**PUBLIC HEALTH ONTARIO STAFF:**
- **Dr. Maureen Cividino**
  - IPAC Physician
- **Tim Cronsberry**
  - Manager, Regional Infection Control Network
- **Shirley McDonald**
  - IPAC Resource Expert/Technical Writer
- **Dr. Samir Patel**
  - Clinical Microbiologist, PHOL
# Table of Contents

Abbreviations .......................................................................................................................... 2

Background .............................................................................................................................. 4

Checklist for Preparedness Before the First MERS-CoV Patient Arrives ................................. 5

Checklist for Components of a Patient Management Plan ......................................................... 6

Guidance for Exposure Follow-up in Acute Care Settings ....................................................... 8

- Laboratory testing .................................................................................................................. 8
- Who requires follow-up? ....................................................................................................... 8
- What follow-up is required? ................................................................................................. 9

References ................................................................................................................................ 11

Bibliography/Further Reading .................................................................................................. 12
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIIR</td>
<td>Airborne Infection Isolation Room</td>
</tr>
<tr>
<td>ARDS</td>
<td>Acute Respiratory Distress Syndrome</td>
</tr>
<tr>
<td>ARI</td>
<td>Acute Respiratory Infection</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td>Middle East Respiratory Syndrome coronavirus</td>
</tr>
<tr>
<td>MOHLTC</td>
<td>Ministry of Health and Long-Term Care</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>PHO</td>
<td>Public Health Ontario</td>
</tr>
<tr>
<td>PIDAC</td>
<td>Provincial Infectious Diseases Advisory Committee</td>
</tr>
</tbody>
</table>
Tools for Preparedness: Triage, Screening and Patient Management for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infections in Acute Care Settings, 4th revision.

This tool is intended to assist frontline health care workers (primarily in Emergency Departments, although the principles are applicable in other urgent care settings) in the identification and immediate management of patients who present with severe acute respiratory infection that may be due to Middle East Respiratory Syndrome coronavirus (MERS-CoV). This tool should be used in conjunction with guidance from the Ministry of Health and Long-Term Care (MOHLTC), available at: www.ontario.ca/novelcoronavirus.

This tool is provided to supplement existing PIDAC documents, including Routine Practices and Additional Precautions in all Health Care Settings and Annex B: Prevention of Transmission of Acute Respiratory Infection in all Health Care Settings. All hospitals are expected to have infection prevention and control programs in place that address Routine Practices (risk assessment, hand hygiene, personal protective equipment, control of the environment, administrative controls), Additional Precautions (specific signage, accommodation and personal protective equipment, dedicated medical equipment, limited transport as well as communication with other departments/agencies) and other interventions for the prevention of transmission of acute respiratory infections.
Background

As of June 30, 2015, 1357 human cases of illness (including at least 486 deaths) due to MERS-CoV have been described in twenty-five countries.\(^1\) The illness usually presents as a severe acute respiratory infection which may be associated with renal failure. Information on the current incidence of MERS-CoV, including an international travel update, may be obtained from the World Health Organization at: www.who.int/csr/disease/coronavirus_infections/en/index.html.

MERS-CoV infection is a zoonotic infection with reservoir in camels. Person-to-person transmission occurs via the droplet-contact route. Transmission has occurred in health care settings to health care workers and other patients, and in households. The majority of MERS-CoV cases are reported from the Middle East, mainly from Saudi Arabia.\(^2\) A large outbreak in the Republic of Korea (182 cases and 32 deaths as of June 27, 2015) resulted from introduction by a returning traveller. There is neither evidence of sustained human-to-human transmission in the community nor evidence of airborne transmission.\(^3\)

Health care providers and acute care facilities around the world should be conducting surveillance to identify cases of MERS-CoV that may present to their facilities, and to prevent transmission from such cases if they occur.\(^3\)
# Checklist for Preparedness Before the First MERS-CoV Patient Arrives

<table>
<thead>
<tr>
<th>DOMANI</th>
<th>ELEMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surveillance</strong></td>
<td>□ Establish institutional responsibility for tracking information about MERS-CoV (and other emerging pathogens).</td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td>□ Ensure that Emergency Department (ED) staff is aware of clinical and exposure screening criteria and is updated as needed regarding case definition and screening for travel history.</td>
</tr>
<tr>
<td></td>
<td>□ Consider audits of ED triage screening.</td>
</tr>
<tr>
<td></td>
<td>□ Provide information to health care providers [particularly nurses, physicians, respiratory therapists; focus on ED and intensive care unit (ICU)] on precautions to be taken for patients with suspect/confirmed MERS-CoV infection.</td>
</tr>
<tr>
<td><strong>Laboratory Readiness</strong></td>
<td>Establish:</td>
</tr>
<tr>
<td></td>
<td>□ A notification system for laboratory regarding suspect patients.</td>
</tr>
<tr>
<td></td>
<td>□ A mechanism for notification and prompt delivery of specimens from suspected patients to your public health laboratory.</td>
</tr>
<tr>
<td></td>
<td>□ A system for communicating results to relevant staff and departments; <strong>a MERS-CoV result should be treated as a critical result.</strong></td>
</tr>
<tr>
<td></td>
<td>□ Safety protocols for laboratory staff who will be handling specimens.</td>
</tr>
<tr>
<td><strong>Communication</strong></td>
<td>□ Draft an outline of a communication plan associated with admission of a suspect/confirmed case.</td>
</tr>
<tr>
<td><strong>Planning</strong></td>
<td>□ Develop a patient management plan.</td>
</tr>
<tr>
<td></td>
<td>□ Review/update plan semi-annually.</td>
</tr>
<tr>
<td><strong>Case Treatment</strong></td>
<td>□ Consider participation in investigations to describe clinical features and epidemiology and investigate new therapy (e.g., <a href="http://isaric.tghn.org">http://isaric.tghn.org</a>).</td>
</tr>
</tbody>
</table>
# Checklist for Components of a Patient Management Plan

<table>
<thead>
<tr>
<th>DOMAIN</th>
<th>ELEMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accommodation</strong></td>
<td>□ Identify appropriate room in ED for patients being investigated for disease. &lt;br&gt;□ Establish timeline for movement of patient out of ED if admission is required.</td>
</tr>
<tr>
<td><strong>Additional Precautions</strong></td>
<td>□ Patients should be accommodated in an airborne infection isolation room (AIIR) when possible. &lt;br&gt;□ Health care workers should use both Droplet/Contact and Airborne Precautions (i.e., use of gown, gloves, eye protection, N95 respirator(^1)). &lt;br&gt;□ Patients should wear a surgical mask during transportation, if tolerated. &lt;br&gt;□ Ensure that precautions are initiated whenever a case is suspected; precautions to be discontinued by infection prevention and control staff or their designate when case is cleared.</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>□ Document the process for confirming that patient meets the case definition and requires testing. &lt;br&gt;□ Consider availability of materials to remind staff how to obtain specimens using appropriate precautions. &lt;br&gt;□ Document the process and communications required for rapid transport and testing of relevant specimens.</td>
</tr>
<tr>
<td><strong>Communication</strong></td>
<td>□ Notify local public health unit and public health laboratory. &lt;br&gt;□ Notify pre-designated internal stakeholders as per plan (e.g., senior management team, Occupational Health, Infection Prevention and Control, Communications, microbiology laboratory).</td>
</tr>
</tbody>
</table>

---

\(^1\) In Ontario, the Ministry of Health and Long-Term Care recommends the use of a fit-tested, seal-checked N95 respirator and AIIR for MERS-CoV. This advice differs from guidance from the Public Health Agency of Canada.
<table>
<thead>
<tr>
<th>DOMAIN</th>
<th>ELEMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education/Training</td>
<td>□ Establish mechanism for updating institution’s knowledge regarding status of MERS-CoV (e.g., MOHLTC guidance).</td>
</tr>
<tr>
<td></td>
<td>□ Define what materials will be needed (e.g., Q&amp;A for ED/ICU staff; email to senior management; reassurance to laboratory staff who will be handling specimens) and who will be responsible for drafting and review.</td>
</tr>
<tr>
<td></td>
<td>□ Define which hospital departments may be providing care and/or provide diagnostic services for the patient and require information (e.g., nursing areas, respiratory therapy, physiotherapy, occupational therapy, nutrition, diagnostic imaging, pastoral care, laboratories, pharmacy, volunteers, security).</td>
</tr>
<tr>
<td></td>
<td>□ Define contractors and external agencies whose employees may have been exposed (e.g., Emergency Medical Services, other first responders, home care services).</td>
</tr>
<tr>
<td></td>
<td>□ Draft messages/information needed for family and visitors in collaboration with local public health unit.</td>
</tr>
<tr>
<td></td>
<td>□ Limit visitors to family and household contacts and provide education on PPE requirements and use.</td>
</tr>
<tr>
<td>Follow-up for Identification of Transmission</td>
<td>□ Consult with public health authorities regarding risk assessment, and develop a plan for follow-up of exposed staff and visitors.</td>
</tr>
<tr>
<td></td>
<td>□ Report to local public health unit to identify and manage relevant out of hospital exposures.</td>
</tr>
<tr>
<td></td>
<td>□ Confirm guidelines for follow-up for staff and patients (e.g., World Health Organization, Public Health Agency of Canada).</td>
</tr>
<tr>
<td></td>
<td>□ Identify staff/patients/visitors who require follow-up.</td>
</tr>
<tr>
<td></td>
<td>□ Report any occupational illness to the Ministry of Labour, the joint health and safety committee (or health and safety representative), and the trade union, if any.</td>
</tr>
</tbody>
</table>
Guidance for Exposure Follow-up in Acute Care Settings

Laboratory testing


Who requires follow-up?

Health care workers are expected to use Routine Practices and Contact, Droplet and Airborne Precautions when at risk of exposure to a confirmed case, a probable case, or persons under investigation and/or the patient’s environment. Following unprotected exposure to a confirmed or probable case, a risk assessment will be conducted by an appropriate infection prevention and control, occupational health or public health professional to determine the need for, and degree of, follow-up and surveillance of a worker.

The following health care workers are a high priority for follow-up:

- A worker who provided direct clinical or personal care to, or examined, a symptomatic confirmed or probable case involving direct face-to-face contact within two metres of the case OR
  - A worker in the same room at the time an aerosol-generating procedure was performed on a confirmed or probable case
  AND
- who was not wearing gown/gloves/eye protection/N95 respirator

Visitors who require follow-up (by local public health unit):

- Visitors at the bedside of a confirmed case for more than 15 minutes without wearing gown/gloves/surgical mask/eye protection (i.e., not adhering to Droplet>Contact Precautions)
What follow-up is required?

For those who require follow-up:

- Assess daily for respiratory symptoms for 14 days (may be active or passive for persons not present in the hospital; those working should be screened at the beginning of each work shift).
- If fever or any respiratory symptoms develop, exclude the individual from work and restrict to home.
- Collect appropriate laboratory specimen for persons under investigation for possible MERS-CoV infection.
- Collect acute (as soon as convenient after exposure is identified) and convalescent (day 21 after last exposure) serology for MERS-CoV antibody testing.

For the most current information, see MOHLTC Guidance for Health Workers and Health Sector Employees, available at: www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/guidance.aspx
Screening and Patient Management Algorithm for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)\(^1\)

**Notes:**
1. This algorithm is intended to be applied to individual cases presenting to Emergency Departments (and urgent care centres) and should not be used to identify clusters. For a complete list of exposure criteria, visit: [www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/guidance.aspx](http://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/guidance.aspx).
2. Acute Respiratory Infection (ARI): Any new onset acute respiratory infection that could potentially be spread by the droplet route (either upper or lower respiratory tract), which presents with symptoms of a new or worsening cough or shortness of breath and often fever (also known as febrile respiratory illness, or FRI). Note that elderly people who are immunocompromised may not have a febrile response to a respiratory infection.
4. PHOL may test patients for MERS-CoV beyond the criteria in the person-under-investigation definition if requested and discussed with the medical microbiologist at PHOL. See PHOL MERS-CoV Test Information Sheet prior to submission of specimens: [www.publichealthontario.ca/en/ServicesAndTools/LaboratoryServices/Pages/Middle-Eastern-Respiratory-Syndrome-Coronavirus-(MERS-CoV).aspx](http://www.publichealthontario.ca/en/ServicesAndTools/LaboratoryServices/Pages/Middle-Eastern-Respiratory-Syndrome-Coronavirus-(MERS-CoV).aspx).

**START**

**Patient has acute respiratory infection\(^2\) (ARI) with or without lower respiratory tract involvement (e.g., pneumonia or ARDS).**

**Routine Practices**

- Initiate Airborne + Droplet/Contact Precautions
- Notify local public health unit
- Test for viral/bacterial respiratory pathogens and send the following specimens to Public Health Ontario Laboratory (PHOL)\(^4\):
  - Nasopharyngeal swab (NPS) AND viral throat swab
  - Sputum, pleural fluid, lung tissue; bronchoalveolar lavage (BAL), if done
  - Blood for serology, acute and convalescent
  - Stool, if diarrhea, in dry sterile container

**Patient is a close contact of a person with ARI who has either travelled to or resided in the Arabian Peninsula\(^3\), or been in a healthcare facility in the Republic of Korea, in the 14 days prior to onset of illness.**

**NO**

**Patient has travelled to, or resided in, the Arabian Peninsula\(^3\), or been in a healthcare facility in the Republic of Korea, in the 14 days prior to onset of illness.**

**YES**

**YES**

**INITIATE DROPLET/CONTACT PRECAUTIONS AND TEST FOR ROUTINE ARI PATHOGENS.**

**Testing for MERS-CoV is positive.**

**YES**

- Continue Airborne + Droplet/Contact Precautions
- Report to local public health unit
- Report occupational illness to Ministry of Labour, joint health and safety committee (or health and safety representative), WSIB and trade union, if any
- Initiate investigation and exposure follow-up

**NO**

**Aetiology has been determined.**

**YES**

- Use precautions specific to the pathogen.
- Continue Droplet/Contact Precautions or pathogen-specific precautions
- Discontinue Airborne Precautions

**NO**
References


Bibliography/Further Reading

1. Information for Health Workers and Health Sector Employers regarding MERS-CoV:

2. Ontario Ministry of Health and Long-Term Care website on MERS-CoV:

3. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Test Information Sheet:
   http://www.publichealthonario.ca/en/ServicesAndTools/LaboratoryServices/Pages/Middle-Eastern-Respiratory-Syndrome-Coronavirus-(MERS-CoV).aspx

4. World Health Organization guidance on MERS-CoV:
   www.who.int/csr/disease/coronavirus_infections/en/


6. U.S. Centers for Disease Control and Prevention Guidance:
   www.cdc.gov/coronavirus/mers/index.html

7. Public Health England Guidance – MERS-CoV:
   www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MERS-CoV/

   No special handling required for diagnostic specimens in hospital laboratories